As a company listed on the Euronext Growth market in Paris, Europlasma undertakes to providing the financial community with regular, transparent and accessible information and in compliance with stock market regulations
Bond financing with a maximum nominal amount of €45 million over 36 months, in the form of OCBSA (bonds convertible into shares with warrants), implying potential dilution of more than 99% of the share capital
Postponement of the publication of the Group’s 2025 financial statements
